| Recruiting | Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL NCT06838832 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | Universal CAR-T Cell Therapy for NHL NCT07248163 | Bioray Laboratories | N/A |
| Not Yet Recruiting | An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell L NCT06721598 | National Research Center for Hematology, Russia | — |
| Recruiting | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) NCT06534437 | Ryvu Therapeutics SA | Phase 2 |
| Recruiting | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical NCT06716164 | Zhejiang University | EARLY_Phase 1 |
| Completed | A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-ce NCT06705530 | National Research Center for Hematology, Russia | Phase 1 / Phase 2 |
| Recruiting | CAR T-cell Therapy in Patients With Renal Dysfunction NCT05909059 | Northside Hospital, Inc. | Phase 2 |
| Recruiting | SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265 | Verismo Therapeutics | Phase 1 |
| Recruiting | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). NCT06213636 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL NCT06346912 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma( NCT06446128 | Shanghai Cell Therapy Group Co.,Ltd | EARLY_Phase 1 |
| Recruiting | SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR NCT06156774 | Fondazione Italiana Linfomi - ETS | — |
| Not Yet Recruiting | A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma NCT06318884 | Sinocelltech Ltd. | Phase 1 |
| Recruiting | Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL NCT06321289 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma NCT06090162 | Swiss Cancer Institute | N/A |
| Recruiting | A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non- NCT06008691 | Fondazione Italiana Linfomi - ETS | — |
| Unknown | The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) NCT06160362 | Henan Cancer Hospital | N/A |
| Unknown | TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL NCT05631912 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma NCT05741359 | Bioray Laboratories | Phase 1 |
| Recruiting | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 NCT05518383 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 |
| Terminated | Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma NCT05050461 | Versailles Hospital | N/A |
| Unknown | Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma NCT04897477 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Unknown | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma NCT05143112 | Shenzhen University General Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-ce NCT04532268 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphoma NCT04435743 | Ruijin Hospital | — |
| Completed | Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma NCT04094142 | Seoul National University Hospital | Phase 2 |
| Unknown | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy NCT03720496 | Timmune Biotech Inc. | Phase 1 |
| Terminated | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Tr NCT03488251 | Molecular Templates, Inc. | Phase 2 |
| Unknown | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 NCT03497533 | Timmune Biotech Inc. | Phase 1 / Phase 2 |
| Unknown | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies NCT02772198 | Sheba Medical Center | Phase 1 / Phase 2 |
| Unknown | CART-19 Immunotherapy in Mantle Cell Lymphoma NCT02081937 | Chinese PLA General Hospital | Phase 1 / Phase 2 |